Daniel N. Swisher, Jr. Sells 2,200 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $68.08, for a total value of $149,776.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Daniel N. Swisher, Jr. also recently made the following trade(s):

• On Friday, January 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $50.54, for a total value of $111,188.00.
• On Tuesday, December 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The stock was sold at an average price of $59.46, for a total value of $130,812.00.

Corcept Therapeutics Stock Up 3.0 %

CORT opened at $70.15 on Thursday. Corcept Therapeutics Incorporated has a fifty-two week low of $20.84 and a fifty-two week high of $71.29. The company has a market capitalization of $7.35 billion, a P/E ratio of 55.68 and a beta of 0.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The firm’s fifty day moving average price is $57.45 and its two-hundred day moving average price is $48.88.

Institutional Trading of Corcept Therapeutics

Institutional investors have recently made changes to their positions in the business. Black Diamond Financial LLC lifted its stake in Corcept Therapeutics by 4.0% during the fourth quarter. Black Diamond Financial LLC now owns 5,200 shares of the biotechnology company’s stock worth $262,000 after purchasing an additional 200 shares during the period. Hancock Whitney Corp raised its holdings in shares of Corcept Therapeutics by 1.2% in the 3rd quarter. Hancock Whitney Corp now owns 22,954 shares of the biotechnology company’s stock worth $1,062,000 after buying an additional 270 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Corcept Therapeutics by 1.1% during the 4th quarter. Arizona State Retirement System now owns 27,270 shares of the biotechnology company’s stock worth $1,374,000 after buying an additional 289 shares during the period. Illinois Municipal Retirement Fund boosted its stake in Corcept Therapeutics by 0.8% in the 4th quarter. Illinois Municipal Retirement Fund now owns 47,527 shares of the biotechnology company’s stock valued at $2,395,000 after buying an additional 368 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC grew its position in Corcept Therapeutics by 5.3% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 8,754 shares of the biotechnology company’s stock valued at $441,000 after acquiring an additional 441 shares during the period. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Corcept Therapeutics in a research report on Friday, February 7th. Canaccord Genuity Group upped their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. Finally, Sandler O’Neill reissued a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $88.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.